Table 2.

Medians and interquartile ranges of assessed parameters at baseline and after 6 months of dupilumab therapy

	Initial TPS ≤ 4	Initial TPS ≥ 5	Total
TPS
Baseline	3 [1–4]	6 [6–7]	4 [2–6]
Month 6	0 [0–0]	2 [1–4]	0 [0–1]
SNOT-22
Baseline	36.5 [23.5–58.8]	52 [35–65]	40 [28–61.5]
Month 6	9.5 [5.5–16]	9.5 [7.3–12]	9.5 [6–14.8]
Sniffin´ sticks
Baseline	6 [3–11]	4 [3–4]	4 [3–9]
Month 6	10 [7–12]	12 [9–12.3]	11 [8–12]
EQ-5D-3L
Baseline	6 [5–7]	6 [5–7]	6 [5–7]
Month 6	5 [5–5]	5 [5–6]	5 [5–6]
PHQ-2
Baseline	1 [0–2]	2 [0–2]	1 [0–2]
Month 6	0 [0–1]	0 [0–0]	0 [0–0.8]
ACT
Baseline	23 [19–24]	19 [14.5–21]	22 [18.5–24]
Month 6	25 [24–25]	24 [22–25]	25 [23–25]
Mini AQLQ
Baseline	5.9 [4.5–6.5]	4.5 [3.8–5.6]	5.6 [4.1–6.3]
Month 6	6.7 [6.5–6.9]	6.6 [5.9–6.9]	6.7 [6.4–6.9]

Numbers indicate medians and numbers in brackets indicate the interquartile ranges

TPS total polyp score, SNOT-22 Sino Nasal Outcome Test 22, EQ5D-3L European Quality of Life Five Dimension 3 Level, PHQ-2 Patient Health Questionnaire 2, ACT Asthma Control Test, Mini AQLQ Mini Asthma Quality of Life Questionnaire